Last reviewed · How we verify

Bupivacaine and Fentanyl

Bnai Zion Medical Center · FDA-approved active Small molecule

Bupivacaine blocks sodium channels to provide local anesthesia, while fentanyl activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief.

Bupivacaine blocks sodium channels to provide local anesthesia, while fentanyl activates opioid receptors to provide analgesia, together delivering regional anesthesia and pain relief. Used for Regional anesthesia and analgesia for surgical procedures, Epidural or spinal anesthesia with enhanced analgesia.

At a glance

Generic nameBupivacaine and Fentanyl
Also known asMarcaine Spinal 0.5% Heavy, Fentanyl-Janssen
SponsorBnai Zion Medical Center
Drug classLocal anesthetic with opioid analgesic combination
TargetVoltage-gated sodium channels (bupivacaine); mu-opioid receptor (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Bupivacaine is a long-acting local anesthetic that inhibits sodium influx in nerve fibers, preventing action potential propagation and blocking sensory and motor transmission in a localized region. Fentanyl is a potent synthetic opioid agonist that binds to mu-opioid receptors in the central and peripheral nervous system to enhance analgesia. The combination provides synergistic anesthetic and analgesic effects for regional anesthesia procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: